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ABSTRACT
Cancer stem cells (CSCs) are key players in bone metastasis. In some renal 
tumors CSCs overexpress the HGF receptor c-MET, speculating that c-MET targeting 
could lead to bone metastasis inhibition. To address this hypothesis we isolated renal 
CD105+/CD24−CSCs, expressing c-MET receptor from a primary renal carcinoma. 
Then, to study their ability to metastasize to bone, we injected renal CSCs in NOD/
SCID mice implanted with a human bone and we tested the effect of a c-MET inhibitor 
(JNJ-38877605) on bone metastasis development. JNJ-38877605 inhibited the 
formation of metastases at bone implant site. We showed that JNJ-38877605 inhibited 
the activation of osteoclasts induced by RCC stem cells and it stimulated osteoblast 
activity, finally resulting in a reduction of bone turnover consistent with the inhibition 
of bone metastases. We measured the circulating levels of osteotropic factors induced 
by RCC stem cells in the sera of mice treated with c-Met inhibitor, showing that  
IL-11 and CCL20 were reduced in mice treated with JNJ-38877605, strongly 
supporting the involvement of c-MET in the regulation of this process. To address the 
clinical relevance of c-MET upregulation during tumor progression, we analysed c-MET 
in renal cancer patients detecting an increased expression in the bone metastatic 
lesions by IHC. Then, we dosed CCL20 serum levels resulting significantly increased 
in patients with bone metastases compared to non-metastatic ones. Collectively, 
our data highlight the importance of the c-MET pathway in the pathogenesis of bone 
metastases induced by RCC stem cells in mice and humans.
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INTRODUCTION
Renal cell carcinoma (RCC) commonly metastasizes 
to bone, indeed 35% of patients with advanced RCC 
develop bone metastases [1]. Bone lesions are osteolytic 
and worsen the prognosis, causing morbidity associated to 
the skeletal related events, such as pathological fractures, 
spinal cord compression or hypercalcemia and requirement 
for surgical treatment or palliative radiotherapy [2–3]. 
Despite the clinical relevance the mechanism by which 
RCC preferentially metastasizes to bone is poorly 
understood. The bone metastatic process requires a 
series of interactions between tumor cells and bone 
microenvironment, which release many factors activating 
bone resorption by osteoclasts (OCs) [4–6]. Recent work 
essentially focused on production of chemokines and 
interleukins by the sites of metastasis, which in turn attract 
cancer cells to explain different tropism for metastatic 
sites.  Classically, this is the case for CCL21/CCR7 
involved in lymph node metastasis, CCL27/CCR10 in 
skin metastasis  or CCL20/CCR6 involved in metastases 
at multiple sites [7–8]. In particular, CCL20 has been 
produced by different cancer cells as pancreatic, breast 
and renal carcinoma [9]. Furthermore, high expression of 
interleukin-11 correlated with poor prognosis in clear-cell 
renal carcinoma, highlighting the clinical relevance of an 
early detection of IL-11 and CCL20 in renal carcinoma 
patients. 
Our group recently demonstrated an important 
role for cancer stem cells (CSCs) in promoting bone 
metastasis formation in breast and lung cancer, opening 
the perspective to target CSCs to prevent or block the bone 
metastatic process [10–11]. Literature reports different 
attempts to characterize CSCs in RCC, resulting in the 
identification of CD105, CXCR4 and ALDH1 as the 
most reliable markers [12–15]. In other tumors as well as 
RCC, the expression of CD105 is related to the ability of 
initiating a metastatic process, for instance in breast cancer 
the subpopulation of cell expressing CD105 correlates 
with a high migratory ability [16] and in hepatocarcinoma, 
CD105 promotes the invasion and metastases of liver 
cancer cells [17]. 
The characterization of different mutations in some 
tyrosine kinases (TKs) expressed by RCC lead to the 
introduction of TK inhibitors in the treatment of RCC 
[18–19], which replaced immunotherapy as the standard of 
care for these patients, changing the therapeutic approach 
of RCC. c-MET, the HGF receptor, is normally involved 
in cell growth, differentiation and neo-vascularization, but 
its dysregulation has been implicated in tumor formation, 
invasion and angiogenesis [20]. In hereditary and sporadic 
papillary RCC patients activating mutations of c-MET have 
been identified [21–23] and over expression of c-MET has 
been also reported in clear cell carcinoma [24–26]. 
Since c-MET mediates the interaction between 
cancer cells and mesenchymal cells of the bone 
microenvironment [27], we propose it as a suitable 
candidate to disrupt bone metastatic process. TK and 
more specific MET inhibitors have been tested and clinical 
trials are ongoing for the treatment of RCC [28–29]. JNJ-
38877605 is a highly selective c-MET ATP competitive 
kinase inhibitor [30], which induces cell death in tumor 
cells overexpressing c-MET protein or expressing 
constitutively activated c-MET protein. The expression of 
c-MET have been described on a RCC cell line derived 
from human bone [31], but its expression on RCC stem 
cells have not been investigated. Here we studied the 
ability of RCC stem cells to metastasize bone through 
a human-in-mice model of bone metastases, where a 
small fragment of human bone was implanted sub-cutis 
in NOD-SCID mice [10–11, 32–33], thereby providing a 
viable and active human microenvironment. Moreover, we 
reported the relevant role of c-MET in the bone metastatic 
process induced by RCC stem cells. Indeed, we were 
able to block the bone metastasis formation in mice by 
inhibiting c-MET with a selective and specific inhibitor, 
JNJ-38877605. Finally, c-Met expression was increased 
in renal cancer patients with bone metastasis and CCL20 
was upregulated in the circulation of the same patients 
supporting the relevance to target c-Met to reduce renal 
cancer-derived bone metastases. 
RESULTS
RCC stem cells express high level of c-MET
RCC stem cells were previously isolated from a 
primary clear cell renal carcinoma as CD105+CD24−
cells and tested for stemness features. The negative 
counterpart CD105-CD24- cells did not show tumorigenic 
activity after injection in SCID mice [12]. We transduced 
CD105+CD24− RCC stem cells with a luciferase-
expressing lentiviral vector and grew them as spheroids 
(Figure 1A). After SC injection these cells originated a 
tumor mass that recapitulated the heterogeneity of the 
primary tumor (Figure 1B), including a subpopulation of 
RCC stem cells expressing CD105 and c-MET (Figure 
1C–1D). The percentage of CD105+/CD24−/c-MET+ 
cells was 65%.
RCC stem cells metastasize to human bone 
To determine the ability of RCC stem cells to directly 
induce bone metastases, we injected them subcutaneously 
(SC), close to the bone implant or through intracardiac 
route (IC) in NOD/SCID mice carrying a small piece of 
human bone, previously implanted in a flank. The number 
of mice in the experimental groups, time of mice survival, 
percentages of bone engraftment, and numbers of lung 
and bone metastases are indicated in Table 1. The human 
bone implants resulted viable, with mineralized areas, 
stromal cells and little or no necrosis evident in the grafts 
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(Figure 2A). Human neo-vascularization was present, with 
numerous vessels expressing human CD34 (Figure 2B). 
RCC stem cells colonized human implanted bone after 
either IC or SC injection (Figure 2C–2D). IHC analysis 
of serial slices showed that tumor cells in bone lesions 
(Figure 2D) expressed CD105 and c-MET (Figure 2E, 2F). 
By isolating tumor cells from the implanted bone, we 
retrieved a cell population resembling the  heterogeneity 
of the primary tumor, with about 10% of CD105+CD24− 
RCC stem cells (Figure 2G). To rule out metastatic seeding 
of RCC stem cells in bones of the hosts, we performed 
X-rays on the mice without detecting lesions in mouse 
bones, demonstrating a species-specific tropism of these 
cells to human bone (Figure S1).
RCC stem cells develop bone metastases with a 
c-MET dependent mechanism 
To investigate whether c-MET has a role in the bone 
metastatic process induced by RCC stem cells, we treated 
mice with JNJ-38877605 (hereafter referred to as JNJ), a 
highly specific c-MET inhibitor, which was not toxic on 
RCC stem cell culture in vitro, also at high concentrations 
as demonstrated by the citoxicity assay (Figure S2). We 
monitored the growth and localization of these cells 
through IVIS, at different time points for 60 days. At 20 
days the primary tumors were macroscopically evident 
and the luciferase signal increased progressively over 
the course of the study. Importantly, JNJ did not grossly 
affect tumor growth, with only a slight reduction in the 
first 20 days after implantation followed prompt alignment 
with untreated controls  (Figure 3A). This result was also 
confirmed by the quantification of the mean luciferase 
intensity (Figure 3B) and of the endpoint tumor mass 
volume (Figure 3C). Of note, while JNJ treatment did 
not influence overall tumor growth kinetics, it manifestly 
inhibited the formation of metastases at bone implant site. 
Indeed, bone lesions were present in untreated mice, but 
they were absent in JNJ-treated mice (Figure 4A, 4B). 
The marked increase in bone remodeling due to bone 
metastases was evaluated through trichrome staining, 
which showed a larger area of new bone apposition 
consequent to the increased metastatic bone resorption in 
untreated mice (blue stain, Figure 4C) compared to JNJ-
treated ones (Figure 4D). 
Altogether these results support our hypothesis 
that RCC stem cells are osteotropic and induce bone 
metastases through the c-MET pathway involvement.
JNJ blocks bone metastasis by inhibiting stem 
cell-induced OC activation
Since renal cancer bone metastases are characterised 
by an increased bone resorption activity, which is mainly 
Figure 1: RCC stem cells. CD105+CD24− RCC stem cells previously isolated from a primary clear cell renal carcinoma grew as 
spheroid (magnification × 40) (A). After SC injection these cells originated a tumor mass that recapitulated the heterogeneity of the primary 
tumor (B), including a subpopulation of RCC stem cells (C) expressing c-MET (D).
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Figure 2: RCC stem cells efficiently metastasize to bone. (A) H&E-stained section in control mice show the viable human bone 
(magnification × 20). (B) IHC staining for human CD34 confirmed the presence of human vascularization (magnification × 20). (C) 
H&E and IHC staining for vimentin confirmed the presence of bone metastasis in mice injected with RCC stem cells through IC route 
(magnification × 20 and × 60). (D–F) Serial slices of the human implanted bone show bone metastasis in mice injected SC with RCC stem 
cells. In the tumor lesions cells express both CD105 (E) and c-MET (F) (magnification × 20). (G) Flow citometry analysis of cells retrieved 
by bone shows a cell population resembling the  heterogeneity of the primary tumor, with about 10% of CD105+CD24− RCC stem cells. 
Table 1: In vivo results following JNJ treatment in tumor bearing mice
Mice group N Bone engrafment Death Lung metastasis Bone metastasis
Bone+CSC+veh 31 30/31 (96,8) 3/31 (9,6%) 7/28 (25%) 15/28 (53,6%)
Bone+CSC+JNJ 19 19/19 (100%) 2/19 (10,5%) 4/17 (23,5%) 0/17
Bone+veh 11 10/11 (90,1) 1/11 (9%) 0/10 0/10
Bone+JNJ 11 10/11 (90,1) 2/11 (18,2) 0/9 0/9
CSC+veh 6 no bone implant 1/6 1/5
CSC+JNJ 6 no bone implant 0/6 1/6
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dependent on OCs, and considering that the c-MET/
HGF pathway is involved in osteoclastogenesis, we 
investigated the effect of JNJ on OCs in vitro, thus 
avoiding interferences of bone microenvironment and 
RCC stem cells. In cultures of human PBMCs kept under 
pro-osteoclastogenic conditions, we added JNJ showing 
that it significantly reduced both the formation of large, 
multinucleated and TRAP+ OCs (Figure 5A) and the 
number of OCs compared to the control (Figure 5B). 
Beside the effect played on OCs in vitro, we addressed 
the effect of JNJ in vivo by performing histomorphometric 
analysis on human bone implants and on mice bones. 
In untreated mice, RCC stem cells caused a significant 
increase of OC activity as demonstrated by the augmented 
percentage of erosion surface, p < 0.001 (Figure 5C), 
suggesting a direct stimulation by RCC stem cells on the OC 
bone resorption activity. The treatment with JNJ resulted in 
a significantly decreased OC activity in mice injected with 
RCC stem cells, p < 0.05 (Figure 5C), whereas JNJ did 
not interfere with OC activity in control mice. This result 
suggests that JNJ indirectly affects OC bone resorption 
activity, because it interferes with RCC stem cell molecular 
signals, which stimulate OC activity. When coupled with 
the in vitro data, these results suggest that Met inhibition has 
a direct negative effect on OC differentiation and an indirect 
effect on OC activity, likely mediated by perturbation of 
paracrine signals from tumor cells.
Since c-MET/HGF pathway is also known to 
regulate osteoblasts (OBs), we investigated the effect of 
JNJ on OB activity in vivo. We observed that RCC stem 
cells did not cause significant changes in the osteoid 
thickness, while JNJ increased it, p < 0.05 (Figure 5D). 
These results suggest that JNJ treatment has an anabolic 
effect, strengthening the relevance to block the c-MET 
pathway in order to contrast the bone metastatic 
commitment of RCC stem cells. 
Figure 3: RCC stem cell growth and in vivo localization. (A) Tumor growth was examined by BLI. Representative images of 
two animals after SC injection of RCC stem cells, at different time points (20, 40, 60 days). (B) At 20 days the primary tumors were 
macroscopically evident and the luciferase signal increased progressively over the course of the study. (C) JNJ did not significantly affect 
tumor growth and the endpoint tumor mass volume.
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JNJ treatment reduces the level of circulating 
osteolytic factors
To investigate the role of c-MET in promoting the 
bone metastatic process we measured the circulating levels 
of osteotropic factors induced by RCC stem cells in the 
sera of mice treated with c-Met inhibitor JNJ. Interestingly 
we were able to quantify the expression in tumor bearing 
mice of the human chemokines IL-11 and CCL20, known 
as key players in the regulation of cancer cell migration 
and progression from different solid tumors [34–36]. 
Importantly, JNJ treatment significantly reduced 
human IL-11. CCL20 levels resulted significantly higher 
in mice untreated with JNJ than in treated ones, p < 0.05 
(Figure 6A–6B), strongly supporting the involvement of 
cMet in the regulation of the bone metastatic process.
c-MET and CCL20 expression are increased in 
renal cancer patients with bone metastases
To further confirm our previous data on humans, we 
analysed c-Met expression in IHC of tumor samples from 
patients with primary renal carcinoma and bone metastases, 
the clinical data of patients are reported in Table S1. c-Met 
was detected on 9/12 primary tumors and in all (4/4) 
bone metastatic samples as shown in (Figure 7A–7D). 
In parallel, to further address the clinical relevance of 
c-Met  upregulation during tumor progression, we dosed 
CCL20 in the serum of renal cancer patients with and 
without bone metastases and in healthy controls. CCL20 
levels significantly increased in the sera of patients with 
bone metastases compared to non-metastatic ones, p 
< 0.05 (Figure 7E). All together these data sustain the 
clinical relevance of targeting c-Met as possible marker of 
renal cancer dissemination to the bone.
DISCUSSION
The cellular mechanisms underlying tumor 
heterogeneity are subject of intense research in the cancer 
biology field. Indeed, cells within the tumour population 
itself often exhibit functional variety with distinct 
proliferative, differentiative and metastatic capacities. 
Figure 4: JNJ inhibits bone metastasis formation. (A) H&E stained section showed bone lesion in untreated mice, (B) whereas no 
bone metastasis was present in JNJ-treated mice. (C) The trichrome staining showed an increased bone remodeling due to bone metastases, 
with a larger area of new bone apposition consequent to the increased metastatic bone resorption in untreated mice (blue stain) compared 
to JNJ-treated ones (D) (magnification × 5). 
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Over recent years increasing data indicated 
the existence of CSCs in multiple solid tumors and 
compelling evidences highlight their role in promoting 
tumor dissemination to distant organs and in particular 
to bone [10–11]. A number of cell surface markers as 
CD133, CD44 or CD24 have been identified and utilized 
for the isolation of subsets enriched for CSCs [37–38]. 
In renal cancer, stem cells have been characterized as 
CD105+CD24− cells [12] and here we demonstrate 
that RCC stem cells directly metastasize to bone in 
NOD/SCID mice, previously implanted with a small 
fragment of human bone [33]. Bone metastasis derives 
by a complex cross-talk between cancer cells and bone 
microenvironment, thereby the presence of a “human 
pre-metastatic niche” as an implanted human bone is 
important to address the mechanisms leading tumor 
progression to bone [39–40].
Recent findings indicate that the MET tyrosine-
kinase receptor is a sensor of adverse microenvironmental 
conditions (such as hypoxia) and drives cell invasion 
and metastasis [41]. In particular, it is involved in 
the bone metastatic process, because it is a mediator 
of the interactions between tumor cells and the bone 
microenvironment in breast cancer [27]. c-MET is widely 
expressed in human cancers [42] and also in CSCs isolated 
from different tumors such as glioblastoma [37], head 
and neck carcinoma [43], pancreatic [44] and colorectal 
cancer [45–46]. Here we report c-MET expression on 
CD105+ CD24− RCC stem cells which, implanted SC 
in NOD-SCID mice, recreate the heterogeneity of the 
primary tumor, including a subpopulation of RCC stem 
cells expressing CD105 and c-MET. Our data suggest 
that c-Met expression on RCC stem cells drives renal 
cancer progression to bone, since c-Met+ RCC stem cells 
Figure 5: Effects of JNJ on osteoclasts (OCs). (A) Human PBMCs cultured under pro-osteoclastogenic conditions differentiated 
into large, multinucleated and TRAP+ OCs, whereas JNJ treatment inhibited OC differentiation. (B) The number of OCs was significantly 
reduced by the JNJ treatment. (C) Histomorphometric analysis on human bone implants showed that RCC stem cells caused a significant 
increase of OC activity (percentage of erosion surface) in mice injected with RCC stem cells compared to control mice (animals not injected 
with RCC stem cells), suggesting a direct stimulation by RCC stem cells on the OC bone resorption activity. JNJ significantly decreased OC 
activity induced by RCC stem cells, p < 0.05. (D) RCC stem cells did not cause significant changes in osteoblast activity (osteoid thickness), 
while JNJ increased it, showing an anabolic effect p < 0.05. ES: erosion surface, BS: bone surface.
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Figure 6: IL-11 and CCL20 serum levels are reduced by JNJ treatment. (A) Human IL-11 and (B) CCL20 serum levels 
resulted significantly higher in mice untreated with JNJ than in treated ones, p < 0.05.
Figure 7: c-MET and CCL20 expression in human samples. (A, C) c-MET expression in primary RCC and (B, D) in bone 
metastastic samples (magnification × 20 and × 60). (E) CCL20 serum levels resulted significantly increased in the sera of patients with bone 
metastases compared to non-metastatic ones, p < 0.05.
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directly formed bone lesions. Furthermore, a selective 
c-MET inhibitor treatment abrogated bone metastases 
development, indicating that HGF/c-MET signalling is 
relevant in the metastatic process induced by RCC stem 
cells. c-MET has been found to be highly expressed in 
prostate cancer bone lesions [47], and a c-MET inhibitor 
reduced bone metastasis progression in breast cancer [48]. 
Thus, our data confirm now a role for c-MET in the RCC-
induced bone metastatic process, suggesting the relevance 
of targeting CSCs in order to avoid disease relapse and 
particularly development of bone metastases. 
A characteristic of  bone metastases from renal 
cancer is the presence of pure lytic lesions due to OC 
activation, accompanied by a striking neo-vascularization 
and by an entire substitution of the bone tissue with 
tumor cells. Here, we observed that RCC stem cells grow 
in the human implanted bone, where they prompt OC 
activation without affecting OB activity. JNJ inhibited the 
stimulatory activity of RCC stem cells on OCs, because it 
likely interferes with paracrine factors produced by RCC 
stem cells, which promote OC bone resorption. JNJ also 
affects OC differentiation and stimulates OB activity, thus 
it has an anabolic effect. This latter point is particular 
relevant because JNJ inhibits the bone metastasis 
formation and concomitantly it has a protective effect 
on bone through an anabolic action. As confirmation of a 
direct effect of c-MET inhibitors on bone metastases and 
bone cells, literature data reported clinical and pre-clinical 
evidences that cabozantinib (a tyrosine kinase inhibitor 
targeting c-MET and VEGFR-2) has a double antitumoral 
and anti-bone resorptive effects in patients with advanced 
RCC [49]. Moreover, Santini et al. demonstrated that 
cabozantinib directly inhibits osteoclasts and reduces 
RANKL expression on osteoblasts [50]. 
Other than the effect of JNJ on RCC stem cells 
and on bone cells, we reported that this c-MET inhibitor 
interferes with serum levels of IL-11 and CCL20. IL-11 
is a negative prognostic factor in renal cancer [34]; 
consistently, we observed that IL-11 levels were higher 
in sera of mice with bone metastasis than in non-bone 
metastasis ones. CCL-20 is expressed by different tumors 
[35–36, 44], where it contributes to cancer cell growth 
and in vivo invasion [45–46]. The link between CCL20 
and CSCs-induced bone metastasis is not known. Here 
we showed that JNJ treatment reduced CCL20 levels in 
the sera of treated animals, which did not develop bone 
metastases, compared to the untreated mice. Finally, for a 
clinical perspective, we reported that CCL20 levels were 
higher in sera of renal cancer patients with bone metastases 
than in non-bone metastatic patients, suggesting a 
potential role of CCL20 in the bone metastases induced 
by RCC stem cells. Moreover, T regulatory (Treg) cells, 
infiltrating renal cancer, express high level of CCR6 [51] 
and its ligand CCL20 is expressed on tumor cells [48], 
representing a homing mechanism for Treg that favours 
the tumor immune escape. Although the function of 
CCL20 in RCC stem cell-mediated bone metastasis needs 
further investigation, it is tempting to speculate that 
blocking CCL20 signaling could be useful to inhibit both 
bone metastases and tumor immune escape.
In conclusion, we provide evidence for the ability 
of RCC stem cells to metastasize bone and we report the 
relevant role of c-MET in the bone metastatic process 
induced by RCC stem cells in mice and humans. Indeed, 
we were able to block the bone metastasis formation in 
mice by inhibiting c-MET with a selective and specific 
inhibitor.
Out of these findings strongly emerges the relevance 
to target CSCs in order to avoid tumor metastases. 
Thus, an integrated approach with the development of 
suitable ex vivo and in vivo models should lead to further 
characterization of the CSCs. High-resolution imaging 
technology together with the identification of stromal 
markers will improve our understanding of CSCs to more 
accurately recapitulate the niche of tumorigenic cells and 
to address novel mechanisms that operate in CSCs during 
tumor progression.
MATERIALS AND METHODS
The human-in-mice model of bone metastasis 
Experimental animals were treated according to 
the national and international guidelines (the Italian 
legislative decree 116/92 and the European Community 
Directive 86/609 CEE) and with the authorization 
provided by the Italian Ministry of Health (as of D.M. 
44/1994-A and subsequent integrations). All of the 
orthotopic xenograft models were established in NOD/
SCID mice as previously described [33]. A small fragment 
of human bone, derived from the discarded femoral head 
of an adult patient submitted to total joint replacement 
(after the patient’s informed consent) was transplanted 
subcutaneously in the left flank of 72 NOD/SCID 
4-week-old female mice (Charles River Laboratories 
Italia). The animals were divided in 3 groups: i) mice 
with bone implant, injected with RCC stem cells and 
treated with JNJ (19) or untreated (31); ii) mice with only 
bone implant treated with JNJ (11) and untreated (11); 
iii) mice only injected with RCC stem cells treated with 
JNJ (6) and untreated (6). RCC stem cells were injected 
subcutaneously (SC) close to the bone implant in 25 
mice and by intracardiac (IC) route in 12 mice. For SC 
injections, 2,0 × 104 RCC stem cells were resuspended 
in PBS and Matrigel 1:2 (BD Biosciences) and injected 
in a volume of 100 μL using a 25-gauge needle. For the 
IC route, 1 × 103 RCC stem cells were injected in the 
left ventricle. The day after the RCC stem cell injection, 
we started a systemic treatment with JNJ by gauvage; the 
compound was administered at a daily dose of 40 mg/kg 
according to previous tested dose [52]. For 60 days, the 
development of tumor masses and metastases to bone and 
Oncotarget45534www.impactjournals.com/oncotarget
other organs was monitored by In Vivo Imaging System 
(IVIS). One of the parameter evaluated to determine 
the viability of the implant bone was the presence of 
circulating human IgG in mice sera by mean of a human 
IgG ELISA, purchased by ICL Inc. 
Lentivirus production and RCC stem cell 
transduction
The production of lentivirus vector and RCC stem 
cell transduction were previously described [10]. Briefly, 
vector stocks were produced by transient transfection of 
the luciferase transfer plasmid, the packaging plasmids 
pMDLg/pRRE and pRSV.REV, and the vesicular stomatitis 
virus (VSV) envelope plasmid pMD2.VSV-G in 293T. 
The viral supernatants were filtered and viral particles 
were concentrated by ultracentrifugation according to 
Follenzi et al. [53]. The viral p24 antigen concentration 
was determined by HIV-1 p24 Core profile ELISA (Perkin-
Elmer Life). The high-titer lentiviruses were added to RCC 
stem cells, which were incubated for 4 hours. RCC stem 
cells were tested for luciferase expression through the 
Luciferase Assay System (Promega Corp.), as described in 
the protocol kit. Importantly, we did not observe significant 
differences in tumor phenotypes associated with lentiviral 
transduction, as demonstrated by histological appearance 
and flow cytometry analysis (data not shown).
In vivo bioluminescence imaging 
To perform IVIS analyses, mice were anesthetized 
by isoflurane inhalation then intraperitoneally injected 
with 15 mg/mL D-luciferin (Caliper Life Science). At 
various time points after tumor implantation (20, 45 and 
60 days), the bioluminescence signals were monitored 
using the IVIS system 2000 series (Xenogen Corp.) 
consisting of a highly sensitive cooled CCD camera. 
Two kinetic bioluminescent acquisitions were collected 
between 0 and 20 min after D-luciferin injection to 
confirm the peak photon emission, which was recorded as 
maximum photon efflux per second; imaging times ranged 
from 1 to 60 sec, depending on the amount of luciferase 
activity. Data were analyzed using the total photon flux 
emission (photons/second) in the regions of interest (ROI) 
defined manually. 
Isolation of bone metastatic cells
After 60 days, the mice were sacrificed, the 
human implanted bones were retrieved, finely minced 
and then digested by incubation for 30 min at 37°C in 
D-MEM containing collagenase I (Sigma-Aldrich) to 
isolate metastatic cells from the osteolytic lesions. After 
collagenase neutralization, the cells were washed by 
Hank’s balanced saline solution (Lonza), and red blood 
cells were lysed with Red Blood cell Lysis Solution 
(Promega). The cell suspension was forced through a 
graded series of meshes to separate the cell components 
from the stroma and aggregates. After filtration, to analyze 
the phenotype of these bone-derived cells, they were 
counted and stained for flow cytometry analysis with 
anti-human CD105PE (Invitrogen) and CD24FITC (BD 
Pharmingen). For every antibody, we also used the relative 
isotype control. Samples were analyzed in a FACs Calibur 
instrument and elaborated by Flowjo (Treestar). 
Single cells were also plated in a serum-free 
DMEM-F12 selective medium (Gibco, Invitrogen) 
supplemented with 10 ng/ml basic fibroblast growth 
factor (b-FGF), 20 ng/ml epidermal growth factor 
(EGF) (PeproTech), 5 μg/ml insulin and 0,4% bovine 
serum albumin (Sigma-Aldrich). After one week, sphere 
formation was observed. Renal spheres were collected by 
gentle centrifugation, disaggregated with a Non-enzymatic 
Cell Dissociation Solution (Sigma-Aldrich), then stained 
with CD105 and CD24 to control the phenotype by FACs 
analysis. 
Immunohistochemistry and histological analysis 
Immunohistochemistry was performed on tissues 
fixed in 10% neutral buffered formalin, and bone 
tissues were decalcified with EDTA treatment until soft. 
Tissues were embedded in paraffin, and sections were 
deparaffinized, rehydrated through graded alcohols and 
subjected to antigen retrieval for immunohistochemistry. 
Sections were stained for H&E for morphological 
studies. The presence of human vessels was demonstrated 
by staining for anti-CD34 (clone QbndN/10) from 
Neomarkers, whereas tumors cells were stained by 
vimentin (clone R9) from DAKO, CD105 (clone 3A9) 
from Novus Biologicals and c-MET (clone C28) from 
Santa Cruz Biotechnology, Inc. To identify the collagen 
fibers on the new bone, a trichrome stain was performed 
by Gomori’s trichrome stain kit (DAKO). TRAP staining 
was performed to identify osteoclasts, according to the 
manufacturer’s instructions (Roche).
Histomorphometry
The samples were fixed in 70% ethanol and 
embedded undecalcified in methyl-methacrylate resin 
(Merck 800590, Germany). Bone sections were cut by using 
a microtome (Polycut S, Leica Microsystems) equipped 
with a carbide-tungsten blade, stained with Goldner’s stain, 
and mounted on microscope slides for histomorphometric 
measurements. The sections were obtained from three 
different levels of the methyl-methacrylate block, each 
separated by a thickness of 250 μm. Histomorphometric 
results were calculated as the mean of the values obtained 
from the three different levels as an approximation of a 3-D 
evaluation. This also avoids replicating the sampling of any 
single bone remodeling unit.
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Measurements were performed by means of an 
image analysis system consisting of an epifluorescent 
microscope (Leica DM2500) connected to a digital 
camera (Leica DFC420 C) and a computer equipped with 
a specific software for histomorphometric analyses (Bone 
3.5, Explora Nova). 
Histomorphometric parameters were reported in 
accordance with the ASBMR Committee nomenclature 
[54]. All thickness/depth results (O.Th, MAR, E.De, 
W.Th) were corrected for obliquity of sections by 
multiplying by π/4.
Serum detection of IL-11 and CCL20 
To analyze the expression of human IL-11 and 
CCL-20 in mice, we utilized the multi-analyte detection 
system Milliplex Map, according to the manufacturer’s 
instructions. Molecule detection was performed with the 
instrument Luminex® 200™ (Luminex Corporation), and 
data were analyzed through the MILLIPLEX analyst 
software.
Statistical analyses
Statistical analyses on multiple simultaneous 
comparison were performed by one way ANOVA, whereas 
differences between two groups were performed by 
Student’s t-test with the Statistical Package for the Social 
Sciences (spssx/pc) software (SPSS, Chicago, IL, USA). 
The results were considered statistically significant for 
p < 0.05.
ACKNOWLEDGMENTS
We thank Antonio Cimino and Daniele Corino for 
technical support in immunohistochemistry.
CONFLICTS OF INTEREST
Comoglio PM and Trusolino L received research 
grants from Janssen, a branch of Johnson&Johnson. Perera 
T is an employee of Janssen. The other authors declare no 
conflict of interest.
FUNDING
This work was supported by CRT Foundation,  by 
the Italian Ministry of Health: Ricerca Sanitaria Finalizzata 
e Giovani Ricercatori 2009 (GR 2009-1584485) and by 
Fondazione Ricerca Molinette ONLUS.
REFERENCES
 1. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, 
Newsham A, Rogerson S, Hayward K, Selby P, Brown J. 
Skeletal complications and survival in renal cancer patients 
with bone metastases. Bone. 2011; 48:160–166.
 2. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, 
Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, 
Vaishampayan UN, Rha SY, Pal SK, Donskov F, et al. 
Impact of bone and liver metastases on patients with renal 
cell carcinoma treated with targeted therapy. Eur Urol. 
2014; 65:577–584.
 3. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, 
Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, 
Ottaviani D, Carteni G, et al. Natural history of malignant 
bone disease in renal cancer: final results of an Italian bone 
metastasis survey. PLoS One. 2013; 8:e83026.
 4. Roato I. Interaction among cells of bone, immune system, 
and solid tumors leads to bone metastases. Clin Dev 
Immunol. 2013; 2013:315024.
 5. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances 
in the biology of bone metastasis: how the skeleton affects 
tumor behavior. Bone. 2011; 48:6–15.
 6. Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, 
Gang M, Su X, Zamani A, Shi Y, Lavine KJ, Ornitz DM, 
Weilbaecher KN, et al. Stromal-Initiated Changes in the 
Bone Promote Metastatic Niche Development. Cell Rep. 
2016; 14:82–92.
 7. Lazennec G, Richmond A. Chemokines and chemokine 
receptors: new insights into cancer-related inflammation. 
Trends Mol Med. 2010; 16:133–144.
 8. Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, Wang H, 
Chen J. Tumor-associated macrophages recruit CCR6+ 
regulatory T cells and promote the development of 
colorectal cancer via enhancing CCL20 production in mice. 
PLoS One. 2011; 6:e19495.
 9. Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, 
Mantovani A. The chemokine receptor switch paradigm and 
dendritic cell migration: its significance in tumor tissues. 
Immunol Rev. 2000; 177:141–149.
10. Bertolini G, D’Amico L, Moro M, Landoni E, Perego P, Miceli R, 
Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, 
Ferracini R, et al. Microenvironment-Modulated Metastatic 
CD133+/CXCR4+/EpCAM− Lung Cancer-Initiating Cells 
Sustain Tumor Dissemination and Correlate with Poor 
Prognosis. Cancer Res. 2015; 75:3636–3649.
11. D’Amico L, Patane S, Grange C, Bussolati B, Isella C, 
Fontani L, Godio L, Cilli M, D’Amelio P, Isaia G, Medico E, 
Ferracini R, Roato I. Primary breast cancer stem-like cells 
metastasise to bone, switch phenotype and acquire a bone 
tropism signature. Br J Cancer. 2013; 108:2525–2536.
12. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. 
Identification of a tumor-initiating stem cell population in 
human renal carcinomas. FASEB J. 2008; 22:3696–3705.
13. Addla SK, Brown MD, Hart CA, Ramani VA, Clarke NW. 
Characterization of the Hoechst 33342 side population from 
normal and malignant human renal epithelial cells. Am J 
Physiol Renal Physiol. 2008; 295:F680–687.
Oncotarget45536www.impactjournals.com/oncotarget
14. Gassenmaier M, Chen D, Buchner A, Henkel L, 
Schiemann M, Mack B, Schendel DJ, Zimmermann W, 
Pohla H. CXC chemokine receptor 4 is essential for 
maintenance of renal cell carcinoma-initiating cells and 
predicts metastasis. Stem Cells. 2013; 31:1467–1476.
15. Ueda K, Ogasawara S, Akiba J, Nakayama M, Todoroki K, 
Sanada S, Suekane S, Noguchi M, Matsuoka K, Yano H. 
Aldehyde dehydrogenase 1 identifies cells with cancer stem 
cell-like properties in a human renal cell carcinoma cell 
line. PLoS One. 2013; 8:e75463.
16. Wang X, Liu Y, Zhou K, Zhang G, Wang F, Ren J. Isolation 
and characterization of CD105+/CD90+ subpopulation in 
breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol. 
2015; 8:5105–5112.
17. Li Y, Zhai Z, Liu D, Zhong X, Meng X, Yang Q, Liu J, 
Li H. CD105 promotes hepatocarcinoma cell invasion and 
metastasis through VEGF. Tumour Biol. 2015; 36:737–745.
18. Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, 
Wang X, Yan X, Guo J. Efficacy and safety of sorafenib 
versus sunitinib as first-line treatment in patients with 
metastatic renal cell carcinoma: largest single-center 
retrospective analysis. Oncotarget. 2016; 7:27044–54. doi: 
10.18632/oncotarget.7395.
19. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, 
Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, 
Wilding G, Cella D, Wagner L, et al. Adjuvant sunitinib or 
sorafenib for high-risk, non-metastatic renal-cell carcinoma 
(ECOG-ACRIN E2805): a double-blind, placebo-
controlled, randomised, phase 3 trial. Lancet. 2016.
20. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 
Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 
2003; 4:915–925.
21. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, 
Kishida T, Zbar B, Vande Woude GF. Activating mutations 
for the met tyrosine kinase receptor in human cancer. Proc 
Natl Acad Sci U S A. 1997; 94:11445–11450.
22. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, 
Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, 
Chidambaram A, Bergerheim UR, et al. Germline and 
somatic mutations in the tyrosine kinase domain of the 
MET proto-oncogene in papillary renal carcinomas. Nat 
Genet. 1997; 16:68–73.
23. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, 
Lubensky I, Zhuang Z, Jeffers M, Vande Woude G, 
Neumann H, Walther M, Linehan WM, Zbar B. Two 
North American families with hereditary papillary renal 
carcinoma and identical novel mutations in the MET proto-
oncogene. Cancer Res. 1998; 58:1719–1722.
24. Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated 
hepatocyte growth factor receptor/c-Met is associated 
with tumor progression and survival in patients with 
conventional renal cell carcinoma. Clin Cancer Res. 2006; 
12:4876–4881.
25. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met 
signaling pathway in renal cancer. Expert Rev Anticancer 
Ther. 2009; 9:785–793.
26. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, 
Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic 
marker and potential therapeutic target in clear cell renal 
cell carcinoma. Ann Oncol. 2013; 24:343–349.
27. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, 
Desiderio MA. Interaction between human-breast cancer 
metastasis and bone microenvironment through activated 
hepatocyte growth factor/Met and beta-catenin/Wnt 
pathways. Eur J Cancer. 2010; 46:1679–1691.
28. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, 
Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, 
Adams LM, Ottesen LH, Laubscher KH, Sherman L, et al. 
Phase II and biomarker study of the dual MET/VEGFR2 
inhibitor foretinib in patients with papillary renal cell 
carcinoma. J Clin Oncol. 2013; 31:181–186.
29. Vigna E, Comoglio PM. Targeting the oncogenic Met 
receptor by antibodies and gene therapy. Oncogene. 2015; 
34:1883–1889.
30. Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, 
Comoglio PM. Ron kinase transphosphorylation sustains 
MET oncogene addiction. Cancer Res. 2011; 71:1945–1955.
31. Weber KL, Pathak S, Multani AS, Price JE. Characterization 
of a renal cell carcinoma cell line derived from a human 
bone metastasis and establishment of an experimental nude 
mouse model. J Urol. 2002; 168:774–779.
32. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, 
Sperandio K, Gauvin GP, Naber SP, Weinberg RA, 
Rosenblatt M. A mouse model of human breast cancer 
metastasis to human bone. Cancer Res. 2005; 65:6130–6138.
33. Roato I, Caldo D, Godio L, D’Amico L, Giannoni P, Morello E, 
Quarto R, Molfetta L, Buracco P, Mussa A, Ferracini R. 
Bone invading NSCLC cells produce IL-7: mice model and 
human histologic data. BMC Cancer. 2010; 10:12.
34. Pan D, Xu L, Liu H, Zhang W, Liu W, Liu Y, Fu Q, Xu J. 
High expression of interleukin-11 is an independent 
indicator of poor prognosis in clear-cell renal cell 
carcinoma. Cancer Sci. 2015; 106:592–597.
35. Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, 
Goke B, Dambacher J. Cell differentiation dependent 
expressed CCR6 mediates ERK-1/2, SAPK/JNK, and 
Akt signaling resulting in proliferation and migration of 
colorectal cancer cells. J Cell Biochem. 2006; 97:709–723.
36. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, 
Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C, 
Keilholz U. Chemokine receptor CCR6 expression level 
and liver metastases in colorectal cancer. J Clin Oncol. 
2006; 24:1910–1916.
37. Boccaccio C, Comoglio PM. The MET oncogene in 
glioblastoma stem cells: implications as a diagnostic marker 
and a therapeutic target. Cancer Res. 2013; 73:3193–3199.
38. Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-
renewal and tumorigenecity of head and neck squamous cell 
carcinoma stem-like cell. Oral Oncol. 2014; 50:633–639.
Oncotarget45537www.impactjournals.com/oncotarget
39. Delitto D, Vertes-George E, Hughes SJ, Behrns KE, 
Trevino JG. c-Met signaling in the development of 
tumorigenesis and chemoresistance: potential applications 
in pancreatic cancer. World J Gastroenterol. 2014; 
20:8458–8470.
40. Boccaccio C, Luraghi P, Comoglio PM. MET-mediated 
resistance to EGFR inhibitors: an old liaison rooted in 
colorectal cancer stem cells. Cancer Res. 2014; 74:3647–3651.
41. Boccaccio C, Comoglio PM. Invasive growth: a MET-
driven genetic programme for cancer and stem cells. Nat 
Rev Cancer. 2006; 6:637–645.
42. Trusolino L, Bertotti A, Comoglio PM. MET signalling: 
principles and functions in development, organ regeneration 
and cancer. Nat Rev Mol Cell Biol. 2010; 11:834–848.
43. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M. 
Breast cancer-derived bone metastasis can be effectively 
reduced through specific c-MET inhibitor tivantinib (ARQ 
197) and shRNA c-MET knockdown. Mol Cancer Ther. 
2012; 11:214–223.
44. Campbell AS, Albo D, Kimsey TF, White SL, Wang TN. 
Macrophage inflammatory protein-3alpha promotes pancreatic 
cancer cell invasion. J Surg Res. 2005; 123:96–101.
45. Schutyser E, Struyf S, Van Damme J. The CC chemokine 
CCL20 and its receptor CCR6. Cytokine Growth Factor 
Rev. 2003; 14:409–426.
46. Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, 
Pikarsky E, Abramovitch R, Zeira E, Galun E, Nagler A, 
Peled A. Interaction between CXCR4 and CCL20 pathways 
regulates tumor growth. PLoS One. 2009; 4:e5125.
47. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, 
Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. 
High expression of the Met receptor in prostate cancer 
metastasis to bone. Urology. 2002; 60:1113–1117.
48. Middel P, Brauneck S, Meyer W, Radzun HJ. Chemokine-
mediated distribution of dendritic cell subsets in renal cell 
carcinoma. BMC Cancer. 2010; 10:578.
49. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, 
Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, 
Roth BJ, Bjarnason GA, Geczi L, et al. Cabozantinib versus 
Everolimus in Advanced Renal-Cell Carcinoma. N Engl J 
Med. 2015; 373:1814–1823.
50. Santini D, Tonini G. Treatment of Advanced Renal-Cell 
Carcinoma. N Engl J Med. 2016; 374:888–889.
51. Oldham KA, Parsonage G, Bhatt RI, Wallace DM, 
Deshmukh N, Chaudhri S, Adams DH, Lee SP. T 
lymphocyte recruitment into renal cell carcinoma tissue: a 
role for chemokine receptors CXCR3, CXCR6, CCR5, and 
CCR6. Eur Urol. 2012; 61:385–394.
52. Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, 
Migliardi G, Molyneux G, Perera T, Comoglio PM, 
Boccaccio C, Smalley MJ, Bertotti A, Trusolino L. Met 
signaling regulates growth, repopulating potential and basal 
cell-fate commitment of mammary luminal progenitors: 
implications for basal-like breast cancer. Oncogene. 2013; 
32:1428–1440.
53. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. 
Gene transfer by lentiviral vectors is limited by nuclear 
translocation and rescued by HIV-1 pol sequences. Nat 
Genet. 2000; 25:217–222.
54. Dempster DW, Compston JE, Drezner MK, Glorieux FH, 
Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, 
Parfitt AM. Standardized nomenclature, symbols, and units 
for bone histomorphometry: a 2012 update of the report of 
the ASBMR Histomorphometry Nomenclature Committee. 
J Bone Miner Res. 2013; 28:2–17.
